United States - English - NLM (National Library of Medicine)

wockhardt limited - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in: 1. short term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short term treatment of active benign gastric ulcer . most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies). famotidine is also indicated for the short term treatment of esoph

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in: 1. short term treatment of active duodenal ulcer . most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. controlled studies in adults have not extended beyond one year. 3. short term treatment of active benign gastric ulcer . most adult patients heal within 6 weeks. studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. short term treatment of gastroesophageal reflux disease (gerd). famotidine is indicated for short term treatment of patients with symptoms of gerd (see clinical pharmacology in adults, clinical studies). famotidine is also indicated for the short term treatment of esoph

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (du). - active gastric ulcer (gu). - symptomatic nonerosive gastroesophageal reflux disease (gerd). - erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2 ) receptor antagonists. risk summary available data with h2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administrat

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: - active duodenal ulcer (du). - active gastric ulcer (gu). - symptomatic nonerosive gastroesophageal reflux disease (gerd). - erosive esophagitis due to gerd, diagnosed by biopsy. famotidine tablets are indicated in adults for the: - treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome, multiple endocrine neoplasias). - reduction of the risk of duodenal ulcer recurrence. famotidine tablets are contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other histamine-2 (h2 ) receptor antagonists. risk summary available data with h2 -receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, no adverse development effects were observed with oral administrat

United States - English - NLM (National Library of Medicine)

cardinal health - famotidine (unii: 5qzo15j2z8) (famotidine - unii:5qzo15j2z8) - famotidine 20 mg - famotidine tablets are indicated in: hypersensitivity to any component of this product. cross sensitivity in this class of compounds has been observed. therefore, famotidine should not be administered to patients with a history of hypersensitivity to other h2 -receptor antagonists.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - famotidine - tablets - famotidine 20 mg - famotidine - famotidine - treatment and prevention of heartburn and hyperacidity in the upper gastrointestinal tract.

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - famotidine - tablets - famotidine 40 mg - famotidine - famotidine - treatment of duodenal ulcer, benign gastric ulcer, pathological hypersecretory conditions such as zollinger-ellison syndrome, gastroesophageal reflux disease. prevention of relapses of duodenal ulceration.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - famotidine -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - famotidine -

Israel - English - Ministry of Health

teva israel ltd - famotidine - tablets - famotidine 40 mg - famotidine - treatment of duodenal ulcer, benign gastric ulcer, pathological hypersecretory conditions such as zollinger-ellison syndrome, gastroesophageal reflux disease. prevention of relapses of duodenal ulceration.